vs

Side-by-side financial comparison of AVADEL PHARMACEUTICALS PLC (AVDL) and Cannae Holdings, Inc. (CNNE). Click either name above to swap in a different company.

Cannae Holdings, Inc. is the larger business by last-quarter revenue ($103.3M vs $77.5M, roughly 1.3× AVADEL PHARMACEUTICALS PLC). AVADEL PHARMACEUTICALS PLC runs the higher net margin — 0.0% vs -90.0%, a 90.1% gap on every dollar of revenue. On growth, AVADEL PHARMACEUTICALS PLC posted the faster year-over-year revenue change (54.9% vs -6.0%). AVADEL PHARMACEUTICALS PLC produced more free cash flow last quarter ($22.2M vs $12.0M). Over the past eight quarters, AVADEL PHARMACEUTICALS PLC's revenue compounded faster (99.6% CAGR vs -3.4%).

Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

Cannae Holdings, Inc. is a diversified holding company that primarily invests in and operates businesses across multiple sectors including financial services, restaurant and hospitality, technology, and healthcare. Its core market is the United States, and it focuses on driving long-term stakeholder value through active portfolio management and strategic operational support for its portfolio companies.

AVDL vs CNNE — Head-to-Head

Bigger by revenue
CNNE
CNNE
1.3× larger
CNNE
$103.3M
$77.5M
AVDL
Growing faster (revenue YoY)
AVDL
AVDL
+60.9% gap
AVDL
54.9%
-6.0%
CNNE
Higher net margin
AVDL
AVDL
90.1% more per $
AVDL
0.0%
-90.0%
CNNE
More free cash flow
AVDL
AVDL
$10.2M more FCF
AVDL
$22.2M
$12.0M
CNNE
Faster 2-yr revenue CAGR
AVDL
AVDL
Annualised
AVDL
99.6%
-3.4%
CNNE

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
AVDL
AVDL
CNNE
CNNE
Revenue
$77.5M
$103.3M
Net Profit
$20.0K
$-93.0M
Gross Margin
15.2%
Operating Margin
2.5%
-23.3%
Net Margin
0.0%
-90.0%
Revenue YoY
54.9%
-6.0%
Net Profit YoY
100.8%
-101.7%
EPS (diluted)
$0.00
$-2.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVDL
AVDL
CNNE
CNNE
Q4 25
$103.3M
Q3 25
$77.5M
$106.9M
Q2 25
$68.1M
$110.2M
Q1 25
$52.5M
$103.2M
Q4 24
$50.4M
$109.9M
Q3 24
$50.0M
$113.9M
Q2 24
$41.5M
$118.0M
Q1 24
$27.2M
$110.7M
Net Profit
AVDL
AVDL
CNNE
CNNE
Q4 25
$-93.0M
Q3 25
$20.0K
$-68.4M
Q2 25
$9.7M
$-238.8M
Q1 25
$-4.9M
$-113.0M
Q4 24
$-5.0M
$-46.1M
Q3 24
$-2.6M
$-13.6M
Q2 24
$-13.8M
$-155.0M
Q1 24
$-27.3M
$-89.9M
Gross Margin
AVDL
AVDL
CNNE
CNNE
Q4 25
15.2%
Q3 25
17.1%
Q2 25
90.7%
17.6%
Q1 25
89.4%
11.8%
Q4 24
90.5%
16.4%
Q3 24
87.7%
18.3%
Q2 24
93.3%
21.9%
Q1 24
94.4%
14.9%
Operating Margin
AVDL
AVDL
CNNE
CNNE
Q4 25
-23.3%
Q3 25
2.5%
-12.3%
Q2 25
13.0%
-55.3%
Q1 25
-5.7%
-20.7%
Q4 24
-6.5%
-20.0%
Q3 24
-0.7%
-15.9%
Q2 24
-30.7%
-19.5%
Q1 24
-95.8%
-36.7%
Net Margin
AVDL
AVDL
CNNE
CNNE
Q4 25
-90.0%
Q3 25
0.0%
-64.0%
Q2 25
14.2%
-216.7%
Q1 25
-9.4%
-109.5%
Q4 24
-10.0%
-41.9%
Q3 24
-5.2%
-11.9%
Q2 24
-33.3%
-131.4%
Q1 24
-100.6%
-81.2%
EPS (diluted)
AVDL
AVDL
CNNE
CNNE
Q4 25
$-2.09
Q3 25
$0.00
$-1.25
Q2 25
$0.10
$-3.93
Q1 25
$-0.05
$-1.81
Q4 24
$-0.04
$-0.75
Q3 24
$-0.03
$-0.22
Q2 24
$-0.14
$-2.49
Q1 24
$-0.30
$-1.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVDL
AVDL
CNNE
CNNE
Cash + ST InvestmentsLiquidity on hand
$91.6M
$182.0M
Total DebtLower is stronger
$70.8M
Stockholders' EquityBook value
$98.2M
$1.0B
Total Assets
$199.4M
$1.3B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVDL
AVDL
CNNE
CNNE
Q4 25
$182.0M
Q3 25
$91.6M
$233.8M
Q2 25
$81.5M
$66.7M
Q1 25
$66.5M
$126.2M
Q4 24
$73.8M
$131.5M
Q3 24
$65.8M
Q2 24
$71.4M
Q1 24
$88.8M
Total Debt
AVDL
AVDL
CNNE
CNNE
Q4 25
$70.8M
Q3 25
$68.6M
Q2 25
$168.4M
Q1 25
$170.6M
Q4 24
$181.0M
Q3 24
$181.2M
Q2 24
$78.2M
Q1 24
$79.3M
Stockholders' Equity
AVDL
AVDL
CNNE
CNNE
Q4 25
$1.0B
Q3 25
$98.2M
$1.2B
Q2 25
$90.7M
$1.4B
Q1 25
$74.1M
$1.7B
Q4 24
$73.8M
$1.8B
Q3 24
$74.7M
$1.9B
Q2 24
$70.3M
$1.9B
Q1 24
$78.4M
$2.3B
Total Assets
AVDL
AVDL
CNNE
CNNE
Q4 25
$1.3B
Q3 25
$199.4M
$1.5B
Q2 25
$187.2M
$1.8B
Q1 25
$167.9M
$2.1B
Q4 24
$164.2M
$2.2B
Q3 24
$158.3M
$2.3B
Q2 24
$157.5M
$2.2B
Q1 24
$167.9M
$2.6B
Debt / Equity
AVDL
AVDL
CNNE
CNNE
Q4 25
0.07×
Q3 25
0.06×
Q2 25
0.12×
Q1 25
0.10×
Q4 24
0.10×
Q3 24
0.10×
Q2 24
0.04×
Q1 24
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVDL
AVDL
CNNE
CNNE
Operating Cash FlowLast quarter
$22.2M
$16.0M
Free Cash FlowOCF − Capex
$22.2M
$12.0M
FCF MarginFCF / Revenue
28.7%
11.6%
Capex IntensityCapex / Revenue
0.0%
3.9%
Cash ConversionOCF / Net Profit
1110.25×
TTM Free Cash FlowTrailing 4 quarters
$-28.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVDL
AVDL
CNNE
CNNE
Q4 25
$16.0M
Q3 25
$22.2M
$-21.6M
Q2 25
$12.7M
$-21.6M
Q1 25
$-8.2M
$9.1M
Q4 24
$7.9M
$-12.0M
Q3 24
$-6.9M
$-31.9M
Q2 24
$-18.2M
$-10.2M
Q1 24
$-29.7M
$-36.0M
Free Cash Flow
AVDL
AVDL
CNNE
CNNE
Q4 25
$12.0M
Q3 25
$22.2M
$-24.1M
Q2 25
$-23.6M
Q1 25
$7.2M
Q4 24
$-14.4M
Q3 24
$-33.6M
Q2 24
$-11.8M
Q1 24
$-37.3M
FCF Margin
AVDL
AVDL
CNNE
CNNE
Q4 25
11.6%
Q3 25
28.7%
-22.5%
Q2 25
-21.4%
Q1 25
7.0%
Q4 24
-13.1%
Q3 24
-29.5%
Q2 24
-10.0%
Q1 24
-33.7%
Capex Intensity
AVDL
AVDL
CNNE
CNNE
Q4 25
3.9%
Q3 25
0.0%
2.3%
Q2 25
1.8%
Q1 25
1.8%
Q4 24
2.2%
Q3 24
0.0%
1.5%
Q2 24
1.4%
Q1 24
1.2%
Cash Conversion
AVDL
AVDL
CNNE
CNNE
Q4 25
Q3 25
1110.25×
Q2 25
1.31×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVDL
AVDL

Segment breakdown not available.

CNNE
CNNE

Reportable Segment Aggregation Before Other Operating Segment$94.9M92%
Other Operating Revenue$8.4M8%

Related Comparisons